dipyridamole has been researched along with Cardiovascular Diseases in 52 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ginkgo leaf extract and dipyridamole injection (GLED), a kind of Chinese herbal medicine preparation, has been considered as a promising supplementary treatment for chronic cor pulmonale (CCP)." | 9.05 | Ginkgo leaf extract and dipyridamole injection for chronic cor pulmonale: a PRISMA-compliant meta-analysis of randomized controlled trials. ( Guo, Y; Qiu, J; Xu, X; Yang, Y; Yue, H, 2020) |
| "Seven hundred and ninety-three consecutive patients symptomatic for chest pain underwent dipyridamole stress-CMR and were followed up for 810 ± 665 days." | 7.83 | Prognostic value of dipyridamole stress cardiac magnetic resonance in patients with known or suspected coronary artery disease: a mid-term follow-up study. ( Agostoni, P; Andreini, D; Aquaro, GD; Baggiano, A; Bartorelli, AL; Beltrama, V; Bertella, E; Conte, E; Giovannardi, M; Gripari, P; Guaricci, AI; Guglielmo, M; Loguercio, M; Masci, PG; Mushtaq, S; Pepi, M; Pontone, G; Rossi, C; Salerni, S; Segurini, C; Veglia, F, 2016) |
| "Aspirin has been convincingly shown to reduce stroke and death in men with transient ischemic attacks (it may possibly be beneficial to women also), myocardial infarction and death in patients with unstable angina, thromboembolic complications associated with artificial heart valves in patients receiving oral anticoagulants (although gastrointestinal bleeding is prohibitive with this combination), and thrombotic occlusion of silicone rubber arteriovenous cannulae in uremic patients undergoing hemodialysis." | 6.15 | Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis. ( Harker, LA, 1986) |
| "Ginkgo leaf extract and dipyridamole injection (GLED), a kind of Chinese herbal medicine preparation, has been considered as a promising supplementary treatment for chronic cor pulmonale (CCP)." | 5.05 | Ginkgo leaf extract and dipyridamole injection for chronic cor pulmonale: a PRISMA-compliant meta-analysis of randomized controlled trials. ( Guo, Y; Qiu, J; Xu, X; Yang, Y; Yue, H, 2020) |
| " With respect to intracranial hemorrhage, aspirin + clopidogrel yielded worse outcomes than 7 treatments, including placebo, apixaban, aspirin, aspirin + dipyridamole, cilostazol, clopidogrel, and dabigatran (OR, 2." | 4.95 | The Efficacy and Safety of 3 Types of Interventions for Stroke Prevention in Patients With Cardiovascular and Cerebrovascular Diseases: A Network Meta-analysis. ( Chang, S; Chang, Y; Lu, S; Sun, Q; Zhang, Y, 2017) |
| "Seven hundred and ninety-three consecutive patients symptomatic for chest pain underwent dipyridamole stress-CMR and were followed up for 810 ± 665 days." | 3.83 | Prognostic value of dipyridamole stress cardiac magnetic resonance in patients with known or suspected coronary artery disease: a mid-term follow-up study. ( Agostoni, P; Andreini, D; Aquaro, GD; Baggiano, A; Bartorelli, AL; Beltrama, V; Bertella, E; Conte, E; Giovannardi, M; Gripari, P; Guaricci, AI; Guglielmo, M; Loguercio, M; Masci, PG; Mushtaq, S; Pepi, M; Pontone, G; Rossi, C; Salerni, S; Segurini, C; Veglia, F, 2016) |
| "Aspirin has been shown to reduce the number of transient ischemic attacks (TIA), stroke and death in patients with multiple TIA." | 3.75 | Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells. ( Turpie, AG, 1982) |
| "Results of recent clinical trials on secondary prevention of ischemic heart disease indicate that judicious, long-term administration of adrenergic beta blockers and platelet-active drugs such as aspirin and Persantine (dipyridamole) would seem to yield protection against mortality associated with acute myocardial infarction, including sudden death." | 3.67 | Clinical trials on the efficacy of pharmacologic intervention reducing mortality from cardiovascular diseases. ( Borhani, NO, 1985) |
| "Aspirin/dipyridamole was more effective than aspirin therapy in reducing BV at shear rates of 1 s(-1) (-3." | 2.73 | Treatment with aspirin and dipyridamole is more effective than aspirin in reducing low shear blood viscosity. ( Rosenson, RS, 2008) |
| "Dipyridamole was introduced on the market as coronary vasodilator drug more than half a century ago and is still used as antithrombotic and vasodilator." | 2.52 | Dipyridamole: a drug with unrecognized antioxidant activity. ( Ciacciarelli, M; Iuliano, L; Violi, F; Zerbinati, C, 2015) |
| "Aspirin therapy was associated with a reduction in the secondary outcome of nonfatal stroke (52 of 2823 vs 76 of 2446; RR, 0." | 2.45 | Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. ( Berger, JS; Hiatt, WR; Kittelson, JM; Krantz, MJ, 2009) |
| " For antiplatelet agents, the most important risk is excess bleeding, especially as emerging evidence suggests that excess bleeding is associated with adverse long-term outcomes; thus prevention and management of excess bleeding is critically important." | 2.45 | Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease. ( Spinler, SA, 2009) |
| "Dipyridamole is a useful agent in 'pharmacological stress' testing in nuclear cardiology imaging and may be valuable when combined with warfarin in certain patient groups, such as those with prosthetic heart valves." | 2.40 | Do we still need dipyridamole? ( Gibbs, CR; Lip, GY, 1998) |
| "(2) Aspirin has essentially gastrointestinal adverse effects, whose incidence can be limited by prescribing a daily dose below 350 mg." | 1.31 | Antiplatelet drugs in cardiovascular prevention: take adverse effects and costs into account. ( , 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 20 (38.46) | 18.7374 |
| 1990's | 6 (11.54) | 18.2507 |
| 2000's | 14 (26.92) | 29.6817 |
| 2010's | 10 (19.23) | 24.3611 |
| 2020's | 2 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Qiu, J | 1 |
| Guo, Y | 1 |
| Xu, X | 1 |
| Yue, H | 1 |
| Yang, Y | 1 |
| Liao, CY | 1 |
| Tan, TL | 1 |
| Lu, YD | 1 |
| Wu, CT | 1 |
| Lee, MS | 1 |
| Kuo, FC | 1 |
| Sun, Q | 1 |
| Chang, S | 1 |
| Lu, S | 1 |
| Zhang, Y | 1 |
| Chang, Y | 1 |
| Kitkungvan, D | 1 |
| Bui, L | 1 |
| Johnson, NP | 2 |
| Patel, MB | 1 |
| Roby, AE | 1 |
| Vejpongsa, P | 1 |
| Babar, AK | 1 |
| Madjid, M | 1 |
| Nacimbene, A | 1 |
| Kumar, S | 1 |
| DeGolovine, A | 1 |
| Gould, KL | 2 |
| Bombardini, T | 1 |
| Costantino, MF | 1 |
| Sicari, R | 2 |
| Ciampi, Q | 1 |
| Pratali, L | 1 |
| Picano, E | 2 |
| Ciacciarelli, M | 1 |
| Zerbinati, C | 1 |
| Violi, F | 1 |
| Iuliano, L | 1 |
| Pontone, G | 1 |
| Andreini, D | 1 |
| Bertella, E | 1 |
| Loguercio, M | 1 |
| Guglielmo, M | 1 |
| Baggiano, A | 1 |
| Aquaro, GD | 1 |
| Mushtaq, S | 1 |
| Salerni, S | 1 |
| Gripari, P | 1 |
| Rossi, C | 1 |
| Segurini, C | 1 |
| Conte, E | 1 |
| Beltrama, V | 1 |
| Giovannardi, M | 1 |
| Veglia, F | 1 |
| Guaricci, AI | 1 |
| Bartorelli, AL | 1 |
| Agostoni, P | 1 |
| Pepi, M | 1 |
| Masci, PG | 1 |
| Rosenson, RS | 1 |
| Berger, JS | 1 |
| Krantz, MJ | 1 |
| Kittelson, JM | 1 |
| Hiatt, WR | 1 |
| Spinler, SA | 1 |
| Kössler, J | 1 |
| Steigerwald, U | 1 |
| Walter, U | 1 |
| Takagi, H | 1 |
| Umemoto, T | 1 |
| Capaldo, B | 1 |
| Galderisi, M | 1 |
| Turco, AA | 1 |
| D'Errico, A | 1 |
| Nosso, G | 1 |
| Sidiropulos, M | 1 |
| de Divitiis, O | 1 |
| Riccardi, G | 1 |
| Gebel, JM | 1 |
| Sdringola, S | 1 |
| Kirkeeide, RL | 1 |
| Cid, E | 1 |
| Gewirtz, H | 1 |
| Valentine, N | 1 |
| Van de Laar, FA | 1 |
| van Driel, ML | 1 |
| Diener, HC | 1 |
| ROSINSKI, J | 1 |
| GONZALEZ MENENDEZ, E | 1 |
| EKESTROEM, S | 1 |
| ABERG, T | 1 |
| Behan, MW | 1 |
| Storey, RF | 1 |
| Betteridge, DJ | 1 |
| Belch, J | 1 |
| Brown, MM | 1 |
| Gent, M | 1 |
| Julian, D | 1 |
| Long, S | 1 |
| Morris, S | 1 |
| Pittard, J | 1 |
| Pye, M | 1 |
| Borges-Neto, S | 1 |
| Tuttle, RH | 1 |
| Shaw, LK | 1 |
| Smith, WT | 1 |
| Jain, D | 1 |
| Coleman, RE | 1 |
| Whellan, D | 1 |
| Moussouttas, M | 1 |
| Papamitsakis, N | 1 |
| Schuler, G | 1 |
| Meadows, TA | 1 |
| Bhatt, DL | 1 |
| Cella, G | 1 |
| Colby, SI | 1 |
| Taylor, AD | 1 |
| McCracken, L | 1 |
| Parisi, AF | 1 |
| Sasahara, AA | 1 |
| Giannini, SD | 1 |
| Sanchis, FS | 1 |
| Guerra, JL | 1 |
| Merusse, JL | 1 |
| Birgens, HS | 1 |
| Hansen, MS | 1 |
| Weiss, HJ | 1 |
| Vane, JR | 1 |
| Moncada, S | 1 |
| Turpie, AG | 1 |
| Boeynaems, JM | 1 |
| Costello, JM | 1 |
| Butcher, RJ | 1 |
| Nassef, LA | 1 |
| Youkey, J | 1 |
| Menapace, FJ | 1 |
| Hajji, L | 1 |
| Aouad, A | 1 |
| Alami, M | 1 |
| Ghannam, R | 1 |
| Ouraoui, T | 1 |
| Sadeli, S | 1 |
| Benjelloun, H | 1 |
| Benomar, M | 1 |
| Gibbs, CR | 1 |
| Lip, GY | 1 |
| Baker, RI | 1 |
| Hankey, GJ | 1 |
| Vanzetto, G | 1 |
| Halimi, S | 1 |
| Hammoud, T | 1 |
| Fagret, D | 1 |
| Benhamou, PY | 1 |
| Cordonnier, D | 1 |
| Denis, B | 1 |
| Machecourt, J | 1 |
| Ripoli, A | 1 |
| Djordjevic-Dikic, A | 1 |
| Di Giovanbattista, R | 1 |
| Minardi, G | 1 |
| Matskeplishvili, S | 1 |
| Ambatiello, S | 1 |
| Pulignano, G | 1 |
| Accarino, M | 1 |
| Lusa, AM | 1 |
| Del Rosso, GF | 1 |
| Pedrinelli, R | 1 |
| Buziashvili, Y | 1 |
| Reverter, JC | 1 |
| Jobin, F | 1 |
| Rubegni, M | 1 |
| Provvedi, D | 1 |
| Bellini, PG | 1 |
| Bandinelli, C | 1 |
| De Mauro, G | 1 |
| Gantmacher, ML | 1 |
| Lane, SE | 1 |
| Lewis, SM | 1 |
| Pippin, JJ | 1 |
| Kosinski, EJ | 1 |
| Campbell, D | 1 |
| Nesto, RW | 1 |
| Hill, T | 1 |
| Borhani, NO | 1 |
| Lavie, CJ | 1 |
| Squires, RW | 1 |
| Gau, GT | 1 |
| Harker, LA | 1 |
| Vormittag, E | 1 |
| Zekert, F | 1 |
| Kohn, P | 1 |
| Grabner, H | 1 |
| Vormittag, D | 1 |
| Duchêne-Marullaz, P | 1 |
| Lavarenne, J | 1 |
| Matusczyk, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Quantification of Myocardial Blood Flow by Positron Emission Tomography in Healthy Volunteers[NCT03895554] | 20 participants (Anticipated) | Observational | 2019-04-01 | Not yet recruiting | |||
| Ammonia N-13 Myocardial Blood Flow Absolute Quantification by Positron Emission Tomography in Patients With Known or Suspected Coronary Artery Disease (Ammonia MAP)[NCT04343209] | 2,500 participants (Anticipated) | Observational | 2020-09-14 | Recruiting | |||
| Quantification of Myocardial Blood Flow by 3D Positron Emission Tomography With High and Low Rate Rb82 Infusion Profiles[NCT05286593] | Phase 4 | 98 participants (Actual) | Interventional | 2021-12-28 | Completed | ||
| The Impact of Coronary Revascularization on Absolute Myocardial Blood Flow as Assessed by Stress Myocardial Positron Tomography[NCT02931331] | 50 participants (Anticipated) | Observational [Patient Registry] | 2016-03-31 | Enrolling by invitation | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
22 reviews available for dipyridamole and Cardiovascular Diseases
| Article | Year |
|---|---|
Ginkgo leaf extract and dipyridamole injection for chronic cor pulmonale: a PRISMA-compliant meta-analysis of randomized controlled trials.
Topics: Cardiovascular Diseases; Chronic Disease; Dipyridamole; Drugs, Chinese Herbal; Ginkgo biloba; Humans | 2020 |
The Efficacy and Safety of 3 Types of Interventions for Stroke Prevention in Patients With Cardiovascular and Cerebrovascular Diseases: A Network Meta-analysis.
Topics: Anticoagulants; Aspirin; Bayes Theorem; Cardiovascular Diseases; Clopidogrel; Dabigatran; Dipyridamo | 2017 |
Dipyridamole: a drug with unrecognized antioxidant activity.
Topics: Animals; Antioxidants; Cardiovascular Diseases; Central Nervous System Diseases; Dipyridamole; Drug | 2015 |
Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials.
Topics: Aspirin; Cardiovascular Diseases; Dipyridamole; Humans; Peripheral Vascular Diseases; Platelet Aggre | 2009 |
Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease.
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Hemorrhage; H | 2009 |
[Anticoagulants of primary haemostasis].
Topics: Anticoagulants; Cardiovascular Diseases; Cerebrovascular Disorders; Dipyridamole; Hemostasis; Humans | 2009 |
Heterogeneity of efficacy and safety of antiplatelet therapy in cardiovascular and cerebrovascular disease.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clinical Trial | 2010 |
Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Diabetes Mellitus, Type 2; Dipyridamole; Drug Therapy | 2012 |
Antiplatelet therapy in cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Platelet Gl | 2004 |
Combination antiplatelet agents in ischemic cerebrovascular disease.
Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Clopidogrel; Dipyridamole; Drug Therapy, Combinati | 2005 |
Clinical aspects of platelet inhibitors and thrombus formation.
Topics: Aspirin; Atherosclerosis; Blood Platelets; Cardiovascular Diseases; Cilostazol; Clopidogrel; Dipyrid | 2007 |
[Prevention of thrombosis by thrombocyte inhibition. 2. Clinical results].
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cerebrovascular Disorders; Clofibrate; Dextrans; | 1980 |
Platelet-active drugs in the secondary prevention of cardiovascular events: an overview.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Coronary Disease; Dipyridamole; Sulfinpyrazone; T | 1980 |
Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cell Division; Clinical Trials as Topic; Coronary | 1982 |
Do we still need dipyridamole?
Topics: Cardiovascular Diseases; Cerebrovascular Disorders; Dipyridamole; Humans; Platelet Aggregation Inhib | 1998 |
Antiplatelet drugs.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Cardiovascular Diseases; Dipyridamole; Humans; Immunoglo | 1999 |
[Platelet antiaggregants].
Topics: Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Dipyridamole; Drug Utilization; Fibrino | 2000 |
[Blood platelets and cardiovascular diseases. IV. Platelet-inhibiting drugs and antithrombotic agents].
Topics: Adenosine Diphosphate; Adrenergic beta-Antagonists; Analgesics; Anti-Inflammatory Agents; Arterioscl | 1976 |
Antiplatelet agents: a review.
Topics: Angina Pectoris; Aspirin; Blood Platelets; Cardiovascular Diseases; Cerebrovascular Disorders; Clofi | 1979 |
Preventive cardiology: what is the value of antiplatelet agents and fish oils?
Topics: Aspirin; Cardiovascular Diseases; Coronary Thrombosis; Dipyridamole; Fish Oils; Humans; Platelet Agg | 1988 |
Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis.
Topics: Anticoagulants; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Cardiovascular Diseases; Clinical | 1986 |
[Recent data on coronary dilators].
Topics: Amino Alcohols; Aminophylline; Animals; Benzofurans; Cardiovascular Diseases; Cats; Coronary Disease | 1968 |
4 trials available for dipyridamole and Cardiovascular Diseases
| Article | Year |
|---|---|
Quantitative myocardial perfusion positron emission tomography and caffeine revisited with new insights on major adverse cardiovascular events and coronary flow capacity.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Aged; Caffeine; Cardiovascular Diseases; Coronary Circula | 2019 |
Treatment with aspirin and dipyridamole is more effective than aspirin in reducing low shear blood viscosity.
Topics: Adult; Aged; Aspirin; Blood Viscosity; Cardiovascular Diseases; Dipyridamole; Female; Hematocrit; Hu | 2008 |
Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cell Division; Clinical Trials as Topic; Coronary | 1982 |
Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis.
Topics: Anticoagulants; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Cardiovascular Diseases; Clinical | 1986 |
28 other studies available for dipyridamole and Cardiovascular Diseases
| Article | Year |
|---|---|
Does preoperative dipyridamole-thallium scanning reduce 90-day cardiac complications and 1-year mortality in patients with femoral neck fractures undergoing hemiarthroplasty?
Topics: Age Factors; Aged; Aged, 80 and over; Body Mass Index; Cardiovascular Diseases; Cohort Studies; Como | 2020 |
End-systolic elastance and ventricular-arterial coupling reserve predict cardiac events in patients with negative stress echocardiography.
Topics: Aged; Blood Pressure; Cardiovascular Diseases; Dipyridamole; Dobutamine; Echocardiography; Exercise; | 2013 |
Prognostic value of dipyridamole stress cardiac magnetic resonance in patients with known or suspected coronary artery disease: a mid-term follow-up study.
Topics: Aged; Cardiovascular Diseases; Chest Pain; Contrast Media; Coronary Artery Disease; Dipyridamole; Ex | 2016 |
Aspirin for prevention of stroke and cardiovascular events among patients with peripheral artery disease.
Topics: Aspirin; Cardiovascular Diseases; Dipyridamole; Humans; Peripheral Vascular Diseases; Platelet Aggre | 2009 |
Coronary vasoreactivity is not altered in young people with type 1 diabetes.
Topics: Adult; Analysis of Variance; Blood Pressure; Cardiovascular Diseases; Case-Control Studies; Coronary | 2010 |
Impact of unexpected factors on quantitative myocardial perfusion and coronary flow reserve in young, asymptomatic volunteers.
Topics: Adult; Age Factors; Asymptomatic Diseases; Cardiovascular Diseases; Chi-Square Distribution; Coronar | 2011 |
Impact of unexpected factors on quantitative myocardial perfusion and coronary flow reserve in young, asymptomatic volunteers.
Topics: Adult; Age Factors; Asymptomatic Diseases; Cardiovascular Diseases; Chi-Square Distribution; Coronar | 2011 |
Impact of unexpected factors on quantitative myocardial perfusion and coronary flow reserve in young, asymptomatic volunteers.
Topics: Adult; Age Factors; Asymptomatic Diseases; Cardiovascular Diseases; Chi-Square Distribution; Coronar | 2011 |
Impact of unexpected factors on quantitative myocardial perfusion and coronary flow reserve in young, asymptomatic volunteers.
Topics: Adult; Age Factors; Asymptomatic Diseases; Cardiovascular Diseases; Chi-Square Distribution; Coronar | 2011 |
Impact of unexpected factors on quantitative myocardial perfusion and coronary flow reserve in young, asymptomatic volunteers.
Topics: Adult; Age Factors; Asymptomatic Diseases; Cardiovascular Diseases; Chi-Square Distribution; Coronar | 2011 |
Impact of unexpected factors on quantitative myocardial perfusion and coronary flow reserve in young, asymptomatic volunteers.
Topics: Adult; Age Factors; Asymptomatic Diseases; Cardiovascular Diseases; Chi-Square Distribution; Coronar | 2011 |
Impact of unexpected factors on quantitative myocardial perfusion and coronary flow reserve in young, asymptomatic volunteers.
Topics: Adult; Age Factors; Asymptomatic Diseases; Cardiovascular Diseases; Chi-Square Distribution; Coronar | 2011 |
Impact of unexpected factors on quantitative myocardial perfusion and coronary flow reserve in young, asymptomatic volunteers.
Topics: Adult; Age Factors; Asymptomatic Diseases; Cardiovascular Diseases; Chi-Square Distribution; Coronar | 2011 |
Impact of unexpected factors on quantitative myocardial perfusion and coronary flow reserve in young, asymptomatic volunteers.
Topics: Adult; Age Factors; Asymptomatic Diseases; Cardiovascular Diseases; Chi-Square Distribution; Coronar | 2011 |
Impact of unexpected factors on quantitative myocardial perfusion and coronary flow reserve in young, asymptomatic volunteers.
Topics: Adult; Age Factors; Asymptomatic Diseases; Cardiovascular Diseases; Chi-Square Distribution; Coronar | 2011 |
Impact of unexpected factors on quantitative myocardial perfusion and coronary flow reserve in young, asymptomatic volunteers.
Topics: Adult; Age Factors; Asymptomatic Diseases; Cardiovascular Diseases; Chi-Square Distribution; Coronar | 2011 |
Impact of unexpected factors on quantitative myocardial perfusion and coronary flow reserve in young, asymptomatic volunteers.
Topics: Adult; Age Factors; Asymptomatic Diseases; Cardiovascular Diseases; Chi-Square Distribution; Coronar | 2011 |
Impact of unexpected factors on quantitative myocardial perfusion and coronary flow reserve in young, asymptomatic volunteers.
Topics: Adult; Age Factors; Asymptomatic Diseases; Cardiovascular Diseases; Chi-Square Distribution; Coronar | 2011 |
Impact of unexpected factors on quantitative myocardial perfusion and coronary flow reserve in young, asymptomatic volunteers.
Topics: Adult; Age Factors; Asymptomatic Diseases; Cardiovascular Diseases; Chi-Square Distribution; Coronar | 2011 |
Impact of unexpected factors on quantitative myocardial perfusion and coronary flow reserve in young, asymptomatic volunteers.
Topics: Adult; Age Factors; Asymptomatic Diseases; Cardiovascular Diseases; Chi-Square Distribution; Coronar | 2011 |
Impact of unexpected factors on quantitative myocardial perfusion and coronary flow reserve in young, asymptomatic volunteers.
Topics: Adult; Age Factors; Asymptomatic Diseases; Cardiovascular Diseases; Chi-Square Distribution; Coronar | 2011 |
Quantitative PET measurements of myocardial blood flow in young, healthy volunteers what should we expect?
Topics: Adult; Age Factors; Asymptomatic Diseases; Cardiovascular Diseases; Coronary Circulation; Dipyridamo | 2011 |
Aspirin therapy should be first-line treatment in secondary prevention of stroke--against.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Drug | 2002 |
[Therapeutic experiences with persantin (possibilities of evaluation of the results of therapy)].
Topics: Cardiovascular Diseases; Dipyridamole; Vasodilator Agents | 1960 |
[Incomplete AV block. Further aspects of its therapy].
Topics: Adrenal Cortex Hormones; Atrioventricular Block; Cardiovascular Diseases; Dipyridamole; Heart Block; | 1963 |
EFFECT OF PERSANTIN ON SPONTANEOUS VENTRICULAR FIBRILLATION IN DOGS IN DEEP HYPOTHERMIA. AN EXPERIMENTAL STUDY.
Topics: Animals; Bradycardia; Cardiovascular Diseases; Dipyridamole; Dogs; Electrocardiography; Heart; Heart | 1963 |
Guidelines on the management of secondary prophylaxis of vascular events in stable patients in primary care.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Bypass; Dipyrida | 2004 |
Outcome prediction in patients at high risk for coronary artery disease: comparison between 99mTc tetrofosmin and 99mTc sestamibi.
Topics: Adenosine; Aged; Cardiovascular Diseases; Coronary Circulation; Coronary Disease; Dipyridamole; Dobu | 2004 |
[Germany's girths in an international comparison].
Topics: Abdominal Fat; Adult; Anthropometry; Aspirin; Aspirin, Dipyridamole Drug Combination; Body Mass Inde | 2005 |
Platelet factor 4 (PF4) and heparin-released platelet factor 4 (HR-PF4) in patients with cardiovascular disorders.
Topics: Adult; Aged; Aspirin; beta-Thromboglobulin; Blood Coagulation Factors; Cardiovascular Diseases; Dipy | 1983 |
[Cardiovascular lesions induced in rats by vitamin D. Possible protective effect of sulfinpyrazone].
Topics: Animals; Arteries; Cardiovascular Diseases; Dipyridamole; Male; Myocardium; Necrosis; Oxyphenbutazon | 1983 |
The anti-thrombotic effects of prostacyclin.
Topics: Animals; Arteries; Aspirin; Cardiovascular Diseases; Dipyridamole; Epoprostenol; Fatty Acids; Hemost | 1980 |
[Prevention of cardiovascular diseases by inhibitors of platelet aggregation (author's transl)].
Topics: Anti-Inflammatory Agents; Aspirin; Cardiovascular Diseases; Dipyridamole; Humans; Platelet Aggregati | 1982 |
Dipyridamole thallium imaging: use in preoperative cardiac risk assessment in vascular surgical patients.
Topics: Aged; Cardiovascular Diseases; Cohort Studies; Dipyridamole; Heart; Humans; Postoperative Complicati | 1993 |
[Dipyridamole stress myocardial scintigraphy].
Topics: Adult; Aged; Cardiovascular Diseases; Coronary Angiography; Dipyridamole; Exercise Test; Female; Hum | 1997 |
Prediction of cardiovascular events in clinically selected high-risk NIDDM patients. Prognostic value of exercise stress test and thallium-201 single-photon emission computed tomography.
Topics: Activities of Daily Living; Aged; Analysis of Variance; Cardiovascular Diseases; Cholesterol; Choles | 1999 |
Perioperative prognostic value of dipyridamole echocardiography in vascular surgery: A large-scale multicenter study in 509 patients. EPIC (Echo Persantine International Cooperative) Study Group.
Topics: Aged; Cardiovascular Diseases; Dipyridamole; Echocardiography; Humans; Middle Aged; Multivariate Ana | 1999 |
Antiplatelet drugs in cardiovascular prevention: take adverse effects and costs into account.
Topics: Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Dipyridamole; Drug Costs; Flurbiprofen; Hum | 2000 |
[Anti-platelet aggregating drugs in the prevention of thromboembolic diseases].
Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents; Cardiovascular Diseases; Cerebrovascular Diso | 1975 |
Predictive value of quantitative dipyridamole-thallium scintigraphy in assessing cardiovascular risk after vascular surgery in diabetes mellitus.
Topics: Angina Pectoris; Cardiovascular Diseases; Diabetic Angiopathies; Dipyridamole; Electrocardiography; | 1989 |
Clinical trials on the efficacy of pharmacologic intervention reducing mortality from cardiovascular diseases.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Clofibrate; | 1985 |
[Medicamentous prophylaxis of postoperative cardiovascular complications (author's transl)].
Topics: Aged; Cardiovascular Diseases; Digitalis Glycosides; Dipyridamole; Female; Humans; Male; Middle Aged | 1974 |
[A new combination--Persumbran--in balneological practice].
Topics: Adult; Aged; Balneology; Cardiovascular Diseases; Dipyridamole; Female; Humans; Male; Middle Aged; O | 1967 |